Quarterly report pursuant to Section 13 or 15(d)

Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.19.3
Note 13 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Revenues, net $ 183,243 $ 162,970
Operating income 33,327 25,763
Costs recognized on sale of acquired inventory 0 (935)
Amortization of acquisition related intangible assets (14,901) (14,276)
Stock-based compensation, inclusive of employer taxes (8,800) (11,565)
Corporate general, selling, and administrative expenses (69,010) (67,051)
Operating Segments [Member]    
Operating income 60,438 57,150
Operating Segments [Member] | Protein Sciences [Member]    
Revenues, net 140,995 126,391
Operating income 59,538 54,614
Operating Segments [Member] | Diagnostics and Genomics [Member]    
Revenues, net 42,552 36,747
Operating income 900 2,536
Intersegment Eliminations [Member]    
Revenues, net (304) (168)
Segment Reconciling Items [Member]    
Acquisition related expenses (1,310) (2,631)
Corporate, Non-Segment [Member]    
Corporate general, selling, and administrative expenses $ (2,100) $ (1,980)